The global c-reactive protein testing market was valued at USD 1.73 billion in 2019 and is expected to reach USD 2 billion by 2027, growing at a CAGR of 1.8% during 2020-2027. The key factors responsible for the c-reactive protein (CRP) testing industry growth include the extensive research being carried out on several applications, the development of novel techniques to analyze the concentration of protein by research scholars, and public-private entities granting funds to expedite research activities in the marketplace. Such factors are expected to positively impact the C-Reactive Protein (CRP) testing market growth.
For instance, in October 2020, researchers at the Baker Institute’s Department of Cardiometabolic Health and the University of Melbourne announced seed funding of USD 200,000 to testing novel drug class “C-reactive protein”, the biomarker for acute inflammation. In the course of development, both will develop anti-inflammatory drugs used to lessen damage from frequent heart attacks, auto-immune disorders, and severe complications from COVID-19.
Know more about this report: request for sample pages
The point-of-care testing methods have become popular in the past few years, as they require lesser time and accurate results in the minimum time. The testing could also be used for a wide variety of healthcare settings. For instance, Abbott’s Afinion PoC and its NycoCard CRP systems both are well suited for hospital use. Moreover, the government initiatives to promote the use of c-reactive protein diagnosis in healthcare settings are bound to drive c-reactive protein testing market growth. The New National Institute of Standards and Technology has enhanced the accuracy of c-reactive protein to assess the risk of heart-related ailments. Moreover, the same recommendations were accorded to the National Institute of Health and Care Excellence to follow best practices and guidelines in the diagnosis of pneumonia.
Furthermore, the approval of c-reactive protein for the diagnosis of viral and bacterial infections has also fueled market growth. c-reactive protein (CRP) is a kind of substance that increases in concentration in response to inflammation and its level is generally higher in bacterial infections, compared to viral ones, however, its utility as a sole biomarker is for bacterial infection is very limited. The concerning funding and product approvals also shaping the marketplace. For instance, in April 2019, SD Biosensor and Innovative New Diagnostics introduced the evaluation of STANDARD Q Malaria/CRP diagnosing method in support of the local authorities. The testing allows the detection of elevated c-reactive protein and malarial infections.
The market has been segmented on the basis of assay type, detection range, disease area, end-use, and region
By Assay Type
By Detection Range
By Disease Area
Know more about this report: request for sample pages
Based on the assay type, the global c-reactive protein testing market is categorized into the immuno-turbidimetric assay, ELISA, chemiluminescence immunoassay, and others. In 2019, the immuno-turbidimetric assay segment accounted for the highest revenue share and is projected to maintain its c-reactive protein (CRP) testing market dominance over the forecast period. The factors attributed to its high share is the wide availability of immuno-turbidimetric based point of care and high sensitivity devices. For instance, the Aidian’s QuikRead goes CRP, which is the rapid immuno-turbidimetric assay to analyze the concentration of c-reactive protein to diagnose infectious diseases. This is also known for its automation, precision, and speed, and level of customization it comes with in the c-reactive protein testing market.
Chemiluminescence immunoassays are projected to witness the highest c-reactive protein (CRP) testing market growth rate over the forecast period. This is due to the benefits offered by such systems. Moreover, such assays are useful in the diagnosis of cardiovascular ailments, and intestinal bowel problems. This prevalence of heart-related ailments due to the changing lifestyle and busy is bound to increase the demand for such assays.
Based on the detection range, the hs-CRP testing segment held a major market share in the global market, in 2019 and is likely to maintain its share over the study period. The testing’s high sensitivity, and ability to accurately measure minute levels of the enzyme to detect inflammations and is preferred in cardio-vascular disorders. Such factors are bound to increase the adoption of such testing. However, the cCRP segment is projected to witness a low penetration rate in the global market, owing to its limited applications in cardio-vascular disorders only. Continuous research and development in the biomarker study are anticipated to improve the segment’s market growth.
North America accounted for the largest revenue share of c-reactive protein (CRP) testing market in 2019. The key factors responsible for the growth include a well-established reimbursement setup in the U.S. and Canada. Both countries have well-known players such as BlueCross and BlueShield for the coverage of inflammation-related problems.
The regional c-reactive protein (CRP) testing market growth is also favored with the cooperation between research institutions in the U.S. and Canada. In October 2020, the U.S.-based Defense Threat Reduction Agency’s (DTRA), Chemical and Biological Technologies (CBT) department in collaboration with the Joint Science and Technology Office (JSTO), as a part of its dedicated role in the Chemical and Biological Defense Program (CBDP), supported the development of the new diagnostic device, which enables clinicians whether the individual is suffering from bacterial or viral infection. The device can evaluate the infection status and type with a small only a small dose of blood from the capillary with a minute finger prick. The device primarily measures three kinds of protein in an infected patient, C-reactive protein, IP-10, and the TRAIL protein.
Asia Pacific region is projected to exhibit impressive growth over the study period. The intellectual research in the region countries has proven the role of the concerned protein in diagnosing bacterial and viral infections, a major biomarker in guiding antibiotics. The combination of the malaria CRP testing is considered a viable substitute testing for malaria. Moreover, it reduces the economic burden on the individual.
Some of the major players operating the c-reactive protein (CRP) testing industry include Merck KGaA; Danaher; Thermo Fisher Scientific, Inc.; Roche Ltd.; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; Siemens; Abbott Laboratories; Abaxis, Inc.; Getein Biotech, Inc.; HORIBA, Ltd.; Randox Laboratories Ltd.; Ortho Clinical Diagnostics; BODITECH MED INC.; and Aidian.